The Sunshine Coast property market is sending a clear message to vendors: price realistically, or wait longer.
Data from recent sales across the region reveals a notable shift in both days on market (DOM) and vendor discounting strategies. Properties in established suburbs like Coolum Beach and Maroochydore are now averaging 32–38 days to sell, compared to 18–22 days recorded in mid-2024. In tighter pockets—Noosa Heads and Sunrise Beach—the slowdown is less pronounced, though even premium beachfront stock is taking longer to find buyers.
"Buyers are no longer competing on emotion," says one Sunshine Coast agent, requesting anonymity. "They're asking harder questions about value, and vendors have to listen."
The shift reflects broader Queensland trends—the state's median sits around $880,000—but the Coast's lifestyle premium, once a buffer against price correction, is eroding as remote work normalises and interstate migration slows. Properties in outer suburbs like Nambour and Sippy Downs, which traded on affordability and growth potential, are particularly affected. Stock there is lingering 45+ days.
Paradoxically, the Maroochydore CBD development is creating micro-markets within the region. New apartment launches have drawn investor and owner-occupier interest, but established residential stock in nearby Mooloolaba is feeling the squeeze, with vendors competing harder for share of wallet.
Auction clearance rates remain steady at 68–72 per cent across the Coast, suggesting the market isn't broken—just recalibrating. Private treaty sales now dominate, allowing vendors flexibility to adjust without public failure.
For buyers, the environment offers genuine leverage. First-home owners, despite concerns that the First Home Owners Grant falls short of purchase barriers, are finding more negotiating room than six months ago. Investors, however, are taking a wait-and-see stance, hoping DOM trends continue upward.
Agents expect the adjustment to stabilise by early spring, assuming lending and employment conditions hold. Until then, vendors should expect patient buyers—and the data to demand fair pricing.
This article was compiled by AI from the sources linked above and screened before publishing. See our editorial standards.